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ABSTRACT
BACKGROUND: A ketogenic diet (KD), which has restricted carbohydrates, sufficient protein,
and a very high fat content, causes the body to switch from a glucose-based metabolism to a
ketone-based metabolism. The KD has been effective at reducing seizures in epileptic patients.
Autism is comorbid with epilepsy and characterized by restricted and repetitive behaviors, low
sociability, and deficits in communication. A strict version of the long-chain triglyceride (LCT)
KD has been effective at reducing autistic symptoms in BTBR T+tf/J, an autistic model of mice.
However, a more moderate and clinically relevant version of the LCT KD has been shown to be
ineffective in this model. Recent studies suggest that a KD derived primarily from medium chain
triglycerides (MCTs) will effectively reduce the severity of autistic symptoms. A MCT KD has
been shown to cause an increase in ketone bodies, acetyl-CoA, and ATP similar to a LCT KD.
However, MCTs are hydrolyzed faster than LCTs and provide more kilocalories per gram of fat,
allowing it to maintain clinical relevancy. Furthermore, only odd-numbered MCTs are
anaplerotic substances, meaning that the metabolites of the Krebs cycle are refilled. Thus, the
goal of the study was to determine a) if either even- or odd-numbered MCTs result in a
beneficial alleviation of autistic symptoms in mice and b) the role of anaplerosis in modifying
behavior and establishing ketosis.

METHODS: BTBR T+tf/J mice were given one of the following metabolic treatments for three
weeks: pellet chow (control), pellet chow balanced with 17% cellulose, 17% heptanoic acid KD
(odd-numbered MCTs), and 17% octanoic acid (even-numbered MCTs). A battery of behavioral
tests was given in order to quantify the core symptoms of autism, including deficits in
sociability, communication, and motor control as well as self-directed repetitive behaviors.
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Furthermore, glucose and ketone blood analysis were conducted in order to elucidate the
mechanisms of the diet.

RESULTS: The mice in the pellet and cellulose control groups did not clearly exhibit autistic
behaviors as expected, primarily in the three-chamber test for sociability and self-directed
repetitive behavior. However, the heptanoic and octanoic treatment groups spent significantly
more time engaged in frontal contact than the cellulose control.

CONCLUSION: The results of the current study are conflicting and inconclusive. The effects of
even- and odd-numbered MCT KDs should be investigated and expanded further in order to
understand the impact of this metabolic treatment on alleviating autistic symptoms.
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INTRODUCTION
Autism
Autism Spectrum Disorders (autism) are pervasive developmental disorders characterized
by deficits in social communication and fixated interests or repetitive behavior. The Diagnostic
and Statistical Manual (DSM) is published by the American Psychiatric Association and lists the
standard criteria used to classify and diagnose mental health disorders. The DSM-IV
differentiated between autistic disorder, Asperger’s disorder, childhood disintegrative disorder,
and pervasive developmental disorder not otherwise specified. However, the recently published
DSM V has now included all of those diagnoses under the criteria for autism (APA, 2013). It is
estimated that autism is prevalent in 70-90/10,000 people or about 1 child out of 125 (French et
al., 2012). Although the prevalence of the disorder has increased significantly from the first
reported value of 4.1/10,000 or about 1 child out of 2,440 (Lotter, 1966), the increase of
prevalence may not be directly linked to an increase in incidence. Evidence suggests that
changes in diagnostic criteria and increased awareness of symptoms of autism are at least partly
responsible for the surge (French et al., 2012). Autism is about five times more prevalent in boys
than girls (CDC, 2014). However, some have argued that this ratio might be overstated; rather,
girls with autism may display different behavioral characteristics and as such, are vastly
underdiagnosed (Wing, Gould, & Gillberg, 2011; Kopp & Gillberg, 1992).
Symptoms of Autism
Autism is extremely heterogeneous in the biological, cognitive, and behavioral domains.
This has been illustrated in studies focused on identical twins with autism who do not have
identical symptoms (Kim & Lord, 2012). There are, however, broad generalities that span the
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diagnosis of autism. Behaviorally, autism is typically characterized by deficits in
communication, socialization, sensory reactivity, and motor skills (Barton et al., 2012).
Cognitively, about 20-50% of children with autism have an intellectual disability or are classified
as mentally retarded (Charman et al., 2011; Chakrabarti & Fombonne, 2005). Furthermore, about
70% of people with autistic disorder have an IQ of below 70 (Coleman, 2000).
Autism is comorbid with a multitude of other behavioral and structural disorders. One
study, which examined comorbidity rates with psychiatric disorders, had a sample size of 112
ten- to fourteen-year old children diagnosed with autism (Simonoff et al., 2008). They found that
70% had at least one comorbid disorder and 41% had two or more, with the most common ones
being social anxiety disorder (29.2%), ADHD (28.2%), and oppositional defiant disorder
(28.1%). Another study found comorbidity rates of 44%, 37%, and 32% for specific phobias,
obsessive compulsive disorder, and ADHD, respectively (Leyfer et al., 2006). Furthermore,
autism is comorbid with epilepsy in 7% to 42%, with more studies suggesting that about onethird of those with autism are also epileptic (Danielsson et al., 2005). Children with autism may
also experience gastrointestinal symptoms, food sensitivities and allergies, and autoimmune
abnormalities (Weber & Newmark, 2007) as well as marked reductions in omega-3 fatty acids
and polyunsaturated fatty acids (Vancassel et al., 2001). They have also been found to have a
smaller corpus callosum (Egaas, Courchesne, & Saitoh, 1995), and lower relative glucose
metabolic rates bilaterally in the thalamus and ventral caudate (Haznedar et al., 2006). fMRI
studies have shown abnormalities in the fusiform face area (Stigler & McDougle, 2012).
Biological markers and early brain abnormalities in children with autism have been reported, but
they are not yet reliable enough to be used in diagnoses (Barton et al., 2012).
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Because of these factors, autism is a behavioral diagnosis that can be made at
significantly different time points. For example, children with autism may start to show
disturbances of movement indicative of autism as early as 4-6 months, or even at birth
(Teitelbaum et al., 1998). However, some toddlers may have regressive autism, meaning they
experience normal development and do not show autistic symptoms, as measured by
developmental delays in social communication, behavior, and sensory abilities, by their first
birthday. However, they begin to display autistic symptoms between the ages of one and two,
suggesting that a second screening is necessary by the second birthday (Landa, Holman &
Garrett-Mayer, 2007).
Causes of Autism
Autism is believed to be caused by genetic and non-heritable factors. About 20% of
people with autism have a genetic etiology, and about 5% show chromosomal aberrations
(Betancur & Coleman, 2012). Furthermore, the prevalence of autism is greater in monozygotic
twins than in dizygotic twin pairs, with 90% and 30% concordance rates, respectively (Folstein
& Rutter, 1977; Bailey et al., 1995). Furthermore, the prevalence of autism in siblings is 3%, and
the rate decreases as the degrees of separation between family members increases (Smalley,
Asarnow & Spence, 1988). In a thorough review, 103 disease genes and 44 recurrent genomic
imbalances were reportedly found in patients with autism (Betancur & Coleman, 2012). Taken
together, the etiology of autism is at least partially based in genetics. However, it may not be a
single gene that is responsible for autism; instead, each gene may be a risk factor for a
component of the disease, with the risk of autism increasing as the number of genes involved
increases (Dawson et al., 2002).
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In a meta-analysis of epidemiological studies, non-heritable factors were found to be
associated with autism, although it is strongly believed that autism is predominately genetically
determined (Sandin et al., 2012). In terms of parental age, the risk of autism in offspring of
mothers who are 35 years or older is 1.3, compared to mothers who are 25-29 years old. The risk
of autism in offspring of fathers who are 40 years or older is 1.4, compared to fathers aged 20-29
years, the risk is 1.7 for fathers who are 50 years or older. The risk also increases with low-birth
weights, pre-term births, and fetal growth restriction. Furthermore, the etiology of autism may be
affected by prenatal exposure to infectious agents, certain maternal medications, prenatal
nutrition status, maternal lifestyle, and exposure to environmental chemicals (Lyall, Schmidt &
Hertz-Picciotto, 2012). Considering the perinatal and prenatal associations and genetic variants,
autism may be strongly linked to epigenetic factors (Persico & Bourgeron, 2006.)
Autism may also be related to metabolic deficiencies and mitochondrial defects. In a
comprehensive literature review examining mitochondrial dysfunction, children with autism had
a 5.0% prevalence rate while the general population has a rate of approximately 0.01%, making
it the most common metabolic abnormality associated with autism (Rossignol & Frye, 2012;
Frye & Rossignol, 2011). However, the prevalence rate of mitochondrial disorders could be
underestimated due to differences in clinical techniques (Giulivi et al., 2010). In a study
comparing 80 autistic and 73 control children, the autistic children had decreased antioxidant
abilities and increased oxidative stress (James et al., 2006). Another study found that autistic
children aged 5-16 years had vitamin insufficiencies and reduced capacities for energy transport,
sulfation, and detoxifaction (Adams et al., 2011). Furthermore, children with autism showed
lower serum carnitine and pyruvate levels and increased ammonia and alanine levels, further
suggesting a mitochondrial defect (Oliveira et al., 2005).
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Treatment Options for Autism
Currently, there is no treatment for autism. However, there are treatments for certain
symptomatic aspects. Behavioral therapy is the most widely used treatment option for the
symptoms of autism (Soorya, Carpenter & Warren, 2012). Behavioral therapy uses
reinforcement theory to teach new skills and reduce problematic behaviors (Lovaas, 1987). There
are specific interventions that address social impairments, communication deficits, and
psychiatric problems (Soorya et al., 2012). For instance, speech therapy is recommended for
those with language deficits, and sensory and auditory integration therapy is recommended for
sensory deficits (Weber & Newmark, 2007). Furthermore, behavioral therapy through virtual
reality has been used as a learning aid to help those with autism interact with the world
(Strickland, 1997).
For those with autism who are also known to have a metabolic abnormality, targeting the
metabolic defect via dietary and vitamin treatments has been shown to be effective (Page, 2000).
For instance, those who have hyperuricosuric autism, or infantile autism combined with a 24hour urate excretion greater than two standard deviations above the mean, have benefited from a
low purine diet (Page, 2000). Autistic children with urinary peptide abnormalities were treated
with a gluten-free, casein-free (GFCF) diet for a year and experienced reduced autistic behavior,
specifically increased social interactions, improved language skills, and increased interest in the
environment (Knivsberg et al., 2003). However, in a randomized, double blind study of 15
autistic patients, the GFCF diet had no effect on alleviating autistic symptoms (Elder et al.,
2006). Furthermore, omega-3 fatty acid supplementation showed significant increases in
language skills and aggressive behavior in autistic children who were not tested for metabolic
defects (Weber & Newmark, 2007) and combined pyridoxine and magnesium supplementation
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improved (but did not completely reverse) autistic symptoms (Page, 2000), suggesting an overall
beneficial role of nutrient supplementation and dietary treatment in autistic children. However,
many dietary and nutrient studies have not been rigorously tested, indicating the need for more
research in this field.
Ketogenic Diet
The ketogenic diet (KD) is comprised of restricted carbohydrates, sufficient protein, and
a very high fat content. It mimics the effects of fasting by minimizing glucose metabolism and
producing and promoting blood ketones. Ketones become the primary source of metabolic fuel
for the brain, bypassing glycolysis, and producing ATP at a much higher rate, causing the body
to enter a state of ketosis (Ruskin et al., 2009).
The KD was developed in 1921 by Wilder as a treatment for intractable epilepsy.
Although its use has waned after the introduction of anti-epileptic drugs (AEDs), a multitude of
studies have demonstrated the efficacy of the diet as a treatment for epilepsy when AEDs do and
do not work. In a multicenter study, it was found that at least 50% of epileptic patients given a
KD experienced a ≥ 50% reduction in seizures (Vining et al., 1998). In a meta-analysis
establishing the efficacy of the KD, 24% of those who adhered on the diet past three months
achieved complete seizure control and 52% of adherers achieved ≥ 90% seizure control
(Henderson et al., 2006). In a three- to six-year follow up on children who were on the diet, 13%
were seizure-free, 14% had a ≥ 90% decrease in seizures, and 19% were free of medications
(Hemingway et al., 2001). In the first randomized control trial, epileptic children who were
placed on the diet had significantly lower baseline seizures and greater seizure reduction
compared to the control group (Neal et al., 2008).
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The diet is slowly administered over the course of five days, according to the Johns
Hopkins protocol. Before the start of the diet, the patient is directed to minimize carbohydrate
intake and begin fasting after dinner. The patient is admitted on the first day, and blood glucose
is measured to ensure levels do not drop below 25 mg/dL. At dinner, the patient is given onethird of the expected full meal. Over the next four days, the quantity of the KD is advanced in
one-third increments (Hartman & Vining, 2007). Medications are tapered off as the effects of the
KD begin to take place, usually within 3-6 months of the diet’s introduction. Because the diet
requires strict compliance for ketosis to be maintained, the KD is a difficult treatment to
implement and often used as a last resort, despite its proven efficacy.
Mechanisms of the KD
The mechanism by which the KD exerts anticonvulsant and antiepileptic effects is not
completely understood, although there have been many proposed theories. In one experiment,
adolescent rats were placed on a control or KD for three weeks (Bough et al., 2006). Microarry
technologies were then used to understand gene expression in the hippocampi, and the data
illustrated that there was upregulation of the genes that encode for energy metabolism enzymes,
suggesting that the KD works by altering mitochondrial gene expression to improve energy
reserves. Moreover, a multi-analysis examining the anticonvulsant efficacy of the KD indicated
that the metabolic adaptations to the KD are fundamentally responsible (Bough & Rho, 2007).
Others hypothesize that raised levels of plasma polyunsaturates (Cunnane et al., 2002), elevated
GABA levels (Yudkoff et al., 2008), diminished reactive oxygen species production (Sullivan et
al., 2004), or reductions in glutamate and increased ketone bodies (Freeman et al., 2007) may be
responsible for the neuroprotective effects of the KD.
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Our lab has explored the involvement of increased adenosine levels (Masino et al.,
2011a; Masino et al., 2011b). An in vivo study of mice on the KD illustrated that increased
intracellular ATP concentrations resulted in reduced extracellular glucose in the hippocampal
CA3 region. The neuronal ATP was released via pannexin channels, and the ATP was
dephosphorylated into adenosine. The resultant activation of the adenosine A1 receptors led to
the opening of the K+ channels (Kawamura et al., 2010). In another study, parents were given a
questionnaire to assess child behavior after participation in events that would increase, decrease,
or have no influence on adenosine levels. Beneficial effects were observed when children
participated in behaviors that increased adenosine levels (Masino et al., 2011a). Discovering the
precise mechanism by which the KD is effective would elucidate etiologies of neurological
disorders that benefit from the KD.
Autism and the KD
As mentioned prior, autism is often comorbid with epilepsy (Buitelaar & WillemsenSwinkels, 2000). This, along with the suggested neuroprotective and neuromodifying effects of
the KD, initiated interest in testing the efficacy of alleviating autistic symptoms with a KD. A
pilot study by Evangeliou et al. (2003) applied the KD to thirty children between the ages of four
and 10. The diet was administered for six months intermittently. All of those who adhered to the
diet reported significant (11%), average (44%), or minor (44%) improvements on the Childhood
Autism Rating Scale. On online survey examining the efficacy of AED and non-AED treatments,
only the KD, Atkin’s or modified Atkin’s diet, gluten-free casein-free diet, and hyperbaric
oxygen therapy were perceived to improve both seizures and behavior (Frye, Sreenivasula, &
Adams, 2011).
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In animal studies, when a strict KD (6.6:1 ratio of fats to proteins and carbohydrates) was
given to a mouse model of autism, impaired sociability, repetitive behaviors, and communication
deficits were alleviated, suggesting that the KD may be used as a therapy for autism (Ruskin et
al., 2013). However, when a moderate KD (3.2:1 ratio of fats to proteins and carbohydrates) was
given to a mouse model of autism, the beneficial alleviation of autistic symptoms was not
observed (Reuman, 2013). In the latter study, the glucose levels were not significantly decreased
compared to the control group whereas they were in the former study. However, the levels of
ketones were increased in both studies. This suggests that the resultant increase in ketone bodies
and/or decrease in glucose levels may be responsible for the beneficial aspects of the KD. As
such, a KD that maintains high ketone levels and low glucose levels, while maintaining clinical
relevancy, could be potentially used as a treatment option for children with autism.
Medium-Chain Triglyceride KD
The classic KD primarily uses long-chain triglycerides (LCTs) as the source of fat and
has a ratio of 3:1 - 4:1 fats to combined proteins and carbohydrates, with the majority of calories
coming from fats (≥ 90%). Because of the high consumption of fats required for the body to
enter ketosis, the diet is not very palatable and can result in undesired side effects, such as
constipation and vomiting. In contrast, a KD comprised of medium-chain triglycerides (MCTs)
requires fewer calories from fat (~35%) for the body to enter ketosis and may be adopted as a
more clinically relevant alternative to the LCT KD.
MCTs are fatty acids with carbon chains ranging from approximately 7 to 12 carbons.
They are usually in the form of oils or soft solids at room temperature. Natural sources of evennumbered MCTs include butter and coconuts. Odd-numbered MCTs are rarely found in nature
but can be synthesized from natural oils.
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Mechanistic basis and clinical relevance of the MCT KD
MCTs can be used in place of, or in conjunction with, LCTs in order to establish ketosis
while maintaining clinical relevance (Labarthe & Des Rosiers, 2008). MCTs have been shown to
cause an increase in ketone bodies, acetyl-CoA, and ATP (de Baulny & Superti-Furga, 2006;
Deng et al., 2009; Borges & Sonnewald, 2012; Brunengaber & Roe, 2006). However, only oddnumbered MCTs are anaplerotic substances. Odd-numbered MCTs are metabolized by βoxidation to produce propionyl-CoA. Propionyl-CoA oxidation results in succinyl-CoA and
oxaloacetate, which refill the Krebs cycle (de Baulny& Superti-Furga, 2006). Furthermore,
propionyl-CoA can produce two molecules of acetyl-CoA, which also refills the Krebs cycle.
The excess carbons are then metabolized by the liver into C4 (acetoacetate and R-βhydroxybutyrate) and C5 (β-ketopentanoate and β-hydroxypentanoate) ketone bodies (Borges &
Sonnewald, 2012; Brunengaber & Roe, 2006; Labarthe & Des Rosiers, 2008). In contrast, evennumbered MCTs are metabolized only into acetyl-CoA molecules and C4 ketone bodies; they do
not refill the Krebs cycle (de Baulny & Superti-Furga, 2006; Deng et al., 2009). Figure 1
provides a brief mechanistic schematic of the way even- and odd-numbered MCTS are
metabolized.
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Figure 1: The relationship
between MCTs, ketone bodies,
and the Krebs cycle. Oddnumbered MCTs form C4 and C5
ketone bodies as well as molecules
of propionyl CoA, which refills the
Krebs cycle. Even-numbered
MCTs only form C4 ketone bodies.
(Adapted from Masino et al., 2009)
	
  

MCTs are hydrolyzed faster and better absorbed than LCTs (Labarthe & Des Rosiers,
2008). Furthermore, MCTs produce more ketones per kilocalorie than LCTs allowing for a
greater allowance of proteins and carbohydrates making it more clinically relevant (Kossof,
Zupec-Kania, and Rho, 2009). As such, patients who are on the MCT KD have an improved
tolerance to the diet as well as fewer negative side effects, such as constipation, compared to the
LCT KD (Kossof et al., 2009). However, other studies have reported abdominal bloating and
diarrhea associated with the MCT KD (Schwartz et al., 1989; Sills et al., 1986). Table 1 provides
an example of a LCT KD and MCT KD meal for comparison purposes while Table 2 provides
the macronutrient composition of a standard diet, strict LCT KD, moderate LCT KD, and MCT
KD given to mice.
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Table 1: Example LCT KD and MCT KD meals (Kossof, Zupec-Kania, & Rho, 2009; Liu &
Wang, 2013)

LCT	
  KD	
  Dinner	
  

MCT	
  KD	
  Lunch	
  

35g	
  36%	
  heavy	
  cream	
  

30g	
  brown	
  rice	
  

Ground	
  beef	
  and	
  cheese:	
  
11g	
  ground	
  beef	
  
10g	
  cheese	
  
8g	
  butter	
  

Salad:	
  
31g	
  lettuce	
  
46g	
  sliced	
  cucumber	
  
26g	
  sliced	
  tomatoes	
  
35g	
  alfalfa	
  sprouts	
  

26g	
  cooked	
  broccoli	
  

30g	
  grilled	
  chicken	
  
cooked	
  in	
  3g	
  canola	
  oil	
  

11g	
  butter	
  

62.5g	
  skim	
  milk	
  
mixed	
  with	
  18.1g	
  MCT	
  oil	
  

1100	
  kcal	
  diet	
  
90%	
  calories	
  from	
  fat	
  

1500	
  kcal	
  diet	
  
71%	
  calories	
  from	
  fat	
  

4:1	
  ratio	
  of	
  fats	
  to	
  
protein	
  and	
  carbohydrates	
  

2.4	
  :1	
  ratio	
  of	
  fats	
  to	
  
protein	
  and	
  carbohydrates	
  

Table 2: Macronutrient composition of various KD used in rodent studies. Approximately
90% of calories come from fat in the moderate LCT KD whereas about 35% of calories come
from fat in the MCT KD (Willis et al., 2010). As a result, the strict LCT KD has the greatest ratio
of fats to protein and carbohydrates; it is 41.25 times greater than the standard diet. In contrast,
the MCT KD has a ratio of fats to proteins and carbohydrates that is only 2.4 times greater than
the standard diet.
	
  

Standard	
  
Diet	
  

Strict	
  LCT	
  
KD	
  

Moderate	
  
LCT	
  KD	
  

MCT	
  KD	
  
	
  

Fats	
  

13.5%	
  

76.7%	
  

65.8%	
  

28.2%	
  

Proteins	
  

28.5%	
  

8.5%	
  

18.1%	
  

23.6%	
  

Carbohydrates	
  

58.0%	
  

3.2%	
  

3.6%	
  

48.1%	
  

Ratio	
  of	
  fats	
  to	
  
proteins	
  and	
  
carbohydrates	
  

0.16:1	
  

6.6:1	
  

3.2:1	
  

0.39:1	
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Diseases of the CNS and the MCT KD
Past and recent studies have indicated that a MCT KD is potentially an effective
treatment for various diseases of the central nervous system (CNS), including epilepsy,
Huntington’s disease, and Alzheimer’s (Kim et al., 2012; Willis et al., 2010; Huttenlocher et al.,
1971; Mochel et al., 2010; Nguen et al., 2013; Aso et al., 2013). In a genetic mouse model of
generalized epilepsy, triheptanoin (at a 35% caloric intake) reduced seizure susceptibility and did
not alter blood glucose (Kim et al., 2012). In a study using pilocarpine-induced status epolepticus
CF1 mice (SE), triheptanoin (at 35% caloric intake for up to 7.5 weeks) was fed to SE and
control mice; triheptanoin was anticonvulsant in the SE mice and the corneal kindling seizure
mouse model (Willis et al., 2010). In children and adolescents with intractable epilepsy, a MCT
diet (octanoic and decanoic acids) decreased rate of seizures (Huttenlocher et al., 1971). In
another study, fifty children with drug resistant epilepsy were treated with a MCT emulsion diet
(to increase palatability), eight achieved complete control of seizures, and fourteen had seizures
reduced by 50-90% with the addition of anticonvulsants (Sills et al., 1986).
Triheptanoic oil (at 40% caloric intake) was given to six patients with Huntington’s
disease for five days, and an increase in serum IGF1 was observed. Because IGF1 is associated
with inhibiting mutant huntingtin toxicity, the increase may restore huntingtin function and have
beneficial effects on those with Huntington’s disease (Mochel et al., 2010). Furthermore,
Huntington’s, in addition to other neurodegenerative diseases, affects motor control and
movement. In one study, Sprague-Dawley rats were subjected to aortic banding, resulting in
pressure-overload induced cardiac hypertrophy. After one week, they were treated with
triheptanoin, which was shown to attenuate their hypertrophy and improve diastolic function and
cardiac glucose oxidation (Nguen et al., 2013).
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In Alzheimer’s patients who lack the APO-ε4 gene (one of the risk factors for
Alzheimer’s), MCT treatment increased cognitive performance on the Alzheimer Disease
Assessment Scale-Cognitive subscale, and for all subjects, higher ketone values were positively
correlated with improvements in paragraph recall; hyperketonemia, as induced by MCTs,
increased cognitive functioning in patients with Alzheimer’s (Reger et al., 2003). Another study
examined the effect of a LCT KD supplemented with MCTs on a familial Alzheimer’s mouse
model. The treatment resulted in improved cognition, illustrated anti-inflammatory properties of
ketone bodies, and improved mitochondrial status (Aso et al., 2013).
Because of the effectiveness MCTs have displayed in diseases of the CNS, specifically
epilepsy as it is comorbid with autism, it is reasonable to assume that a state of ketosis as
induced by MCTs would result in beneficial effects in a mouse model of autism. Furthermore,
the diet is much more clinically relevant as it allows for a greater allowance of proteins and
carbohydrates, suggesting that it would be more palatable and result in higher levels of
compliance.
BTBR T+tf/J Mouse Model of Autism
Physical and Genetic Characteristics
BTBR mice are an inbred strain of mice carrying the wildtype T (brachyury) gene and the
tufted hair (tf) mutation. They have been shown to exhibit genetic and physical characteristics
similar to those with autism. In regards to brain anatomy, BTBR mice have an absent corpus
callosum, and a reduced corpus callosum was present in individuals with autism (Wahlsten,
Metten, & Crabbe, 2003; Egaas, Courchesne, & Saitoh, 1995).Furthermore, BTBR mice have
reduced BDNF mRNA levels, primarily in the dentate gyrus, as well as decreased neurogenesis
in the hippocampus (Silverman et al., 2006; Stephenson et al., 2011). Similarly, those with
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autism have hippocampal abnormalities, namely reductions in the right posterior hippocampus
(Nicolson et al., 2006). The hippocampus is important for memory, emotional behavior, and
information processing; deficits in all three of these areas are characteristic of patients with
autism.
In terms of genetics, BTBR mice have one gene that expresses a single nucleotide
polymorphism (SNP) which differentiates them from the B6 control mice group. The Kmo gene
encodes for kynurenine 3-hydroxylase, an enzyme that regulates the metabolism of kynureic acid
(Meyza et al., 2003; McFarlane et al., 2008). Kynureic acid, an antagonist of glutamate and
nicotine receptors, may promote neuroprotection, dendritic spine formation, and dopamine
release (McFArlane et al., 2008). Altered levels of kynueric acid were also found in patients with
schizophrenia, Huntington’s disease, and Alzheimer’s disease (Linderholm et al., 2012; Beal et
al., 1992; Guillemin & Brew, 2002). Furthermore, BTBR mice have a deletion of the Disc1
mutation, which has been linked to male patients with Asperger syndrome and Schizophrenia
(Kilpinen et al., 2007).
Behavioral characteristics
Through a number of studies, BTBR mice have been shown to exhibit behavioral deficits
that are similar to the core symptoms of autism. BTBR mice display deficits in social
interactions, increased levels of self-directed repetitive behaviors, and impairments in
communication and motor control.
In regards to sociability, BTBR mice have shown decreased sociability in the threechamber sociability test and impaired juvenile play compared to control mice (McFarlane et al.,
2008; Moy et al., 2004; Silverman et al., 2010). In studies that assess repetitive behaviors, BTBR
mice are found to groom more than control mice (McFarlane et al., 2008; Pearson et al., 2011;
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Silverman et al., 2010). However, it has been noted that this response may be normal as this
strain of mice has a mutation in the tufted gene, resulting in hair loss; as such, the increased
grooming behaviors might be a natural response to increased itching (Pearson et al., 2011).
Additionally, BTBR mice have shown communication deficits comparable to those with autism.
BTBR mice produce an unusual pattern of vocalization that is similar to atypical vocalizations
produced by infants with autism (Scattoni et al., 2008). Male BTBR mice display minimal
ultrasonic vocalization responses and reduced scent marking when exposed to female urine
(Wöhr, Roullet, & Crawley, 2011). Furthermore, the BTBR mice fail to socially transmit food
preferences to their cage mates (McFarlane et al., 2008). Lastly, BTBR mice demonstrate low
levels of performance on the rotarod task, which is a measure of motor coordination and balance;
patients with autism may demonstrate impaired motor learning, including problems with
coordination and balance and gait disturbances (Moy et al., 2004; Jansiewicz et al., 2006;
Kielinen et al., 2004).
Thesis Overview and Hypothesis
The success with the strict LCT KD on alleviating autistic symptoms in the BTBR mouse
model of autism is a very promising study that illustrates the potential for novel therapies to treat
the symptoms of autism. However, the more moderate LCT KD was not able to replicate these
results. Although the mechanism by which the KD works is unknown, recent evidence suggests
that ketosis may lead to improved behavioral symptoms of autism. As such, it is reasonable to
assume that a MCT KD would produce a similar level of ketosis and effectiveness at
ameliorating autistic symptoms in a mouse model of autism, while maintaining clinical
relevance. To analyze this theory, we studied the behavior of BTBR mice fed an odd-numbered
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MCT KD, an even-numbered MCT KD, a diet balanced with cellulose, and a control diet pellet
diet.
The current study was designed to (1) investigate the efficacy of a MCT KD on
ameliorating autistic symptoms in a mouse model of autism, and (2) determine the effect of
anaplerosis and the potential role it plays in the mechanistic action of the KD.
(1) We hypothesized that BTBR mice fed a 17% odd-numbered MCT KD (heptanoic
acid) and a 17% even-numbered MCT KD (octanoic acid) would have improved
sociability, motor, and communication skills and decreased repetitive behaviors. This
was based on studies that suggest a MCT KD is more effective than a LCT KD in
terms of metabolism as well as the assumption that the mice would undergo a similar
level of ketosis as the mice treated with a strict LCT KD.
(2) Recent studies suggest that anaplerosis is more effective than ketosis alone in
producing ATP, ketone bodies, and acetyl CoA. Therefore, we predicted that the oddnumbered MCT KD would be more effective than the even-numbered MCT KD at
ameliorating autistic symptoms in the BTBR mouse model of autism.

METHODS
Animals and test procedures
BTBR (Jackson Laboratories) male mice were weaned at P21. Two to six animals were
housed in cages with enrichment toys, given food and water ad libitum, and kept on a 12hr:12hr
light:dark cycle. Starting at five weeks of age, the mice were randomly assigned to one of the
following groups: 17% cellulose, 17% heptanoic acid, 17% octanoic acid, and pellet chow
(LabDiet 5001). The first three diets were created by mixing powdered pellet chow and, by
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weight, 17% heptanoic acid (oil), 17% octanoic acid (oil), and 17% cellulose powder,
respectively. Water was added to the mixture, and pellets were then hand-formed and dehydrated
on high heat for 12-18 hours. The mice were placed on the dietary treatment for three weeks
before behavioral testing began. The heptanoic and octanoic treatment had a ratio of 0.39:1 fats
to carbohydrates and proteins whereas the pellet and cellulose diets had a ratio of 0.16:1.
Weight, food intake, ketone levels, and glucose levels were recorded. Four different
behavioral tests were run: the three-chamber sociability test measured social interaction skills of
mice, the single-grooming test assessed self-directed repetitive behaviors, the social transmission
of food preference (STFP) evaluated communication skills, and rotarod testing measured relative
motor control. Behavioral testing was performed between eight and ten weeks of age between
10:00 am and 4:00 pm.
Weight and food intake
Body weights of each mouse were measured before treatment (five weeks of age) as well
as before any testing began (eight weeks of age). Daily food intake of each cage was measured
weekly, and then divided among the number of mice per cage to derive an estimate of how much
each mouse ate. All four weeks of data was collapsed across time to approximate the amount of
food eaten on a daily basis over the three weeks per mouse.
Ketone and glucose levels
Blood glucose and ketone (β-hydroxybutyrate) levels were measured before treatment
began and at eight weeks of age. The mice were anesthetized by placing them in a small plastic
container with isofluorane. Blood was then taken from the tail vein using a razor blade. The mice
were placed back into their home cage to recover. The blood was analyzed using a Precision Xtra
glucose/ketone meter and strips.
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Three-chamber sociability test
The three-chamber sociability test quantifies preference for social interactions and social
novelty (Crawley, 2004; Moy et al., 2004). The apparatus was made of Plexiglas and consisted
of three chambers of equal size (42.5 cm X 19.1 cm X 22.2 cm). Two side chamber doors with
glass blockers were present. They were used to separate the center chamber from the side
chambers. A wire cage (inverted pencil cup) was placed in the far back corners of the side
chambers. A cement block sat atop the wire cages. The cages and blocks were present during the
entirety of testing.

Figure 2: The three-chamber sociability test. A) Two stranger mice habituate to their
individual cages for thirty minutes. B) The subject mouse habituates to the center chamber for
ten minutes with the side chamber doors closed. The doors are then opened and the mouse
habituates to the entire chamber for ten minutes (phase 1). C) One strange mouse is placed into a
wire cage in one of the side chambers, and the chamber doors are open for ten minutes (phase 2).
D) A second stranger mouse is placed into a wire cage in the remaining side chambers, and the
chamber doors are open for ten minutes (phase 3) (Svedova, 2011).
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Before testing began, the cage of subject mice was placed in the testing room for thirty to
habituate. During that time period, the two stranger mice (adult, male, wild-type C57BL6 control
mice) were placed in wire cages in each chamber side (Figure 2A). After habituation, the
stranger mice were placed back into their home cage, and the apparatus was washed with warm
water and soap.
The subject mouse was then placed in the center chamber with the chamber doors down
for ten minutes in order to habituate. After this period, the thirty-minute three-chamber
sociability test began. During the first ten-minute period (phase 1), the side chamber doors were
removed, and the mouse was free to roam about the entire chamber (Figure 2B). The time spent
in each chamber, defined as over half of the body in the chamber, was recorded to ensure that the
mouse did not have a side preference.
Next, the side chamber doors were replaced, and the subject mouse was placed in the
middle chamber. A stranger mouse was randomly assigned to one side and placed under the wire
cage. The side chamber doors were removed, indicating the start of phase 2 (Figure 2C). The
purpose of phase 2 was to quantify preference for social interaction. The time spent in the
chamber with the stranger mouse, the target chamber, was compared to the time spent in the
empty chamber. After ten minutes had passed, the side chamber doors were again replaced, and
the subject mouse was placed in the center chamber. The second stranger mouse was placed in
the remaining chamber under the wire cage and cement block (Figure 2D). The side chamber
doors were removed. This ten-minute third phase tested the subject mouse’s preference for social
novelty. The amount of time spent in the chamber with the novel stranger mouse (target
chamber) was compared to the amount of time spent with the “old” stranger mouse.
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Phases 1, 2, and 3 were video recorded. The time spent in each chamber was manually
recorded by two scorers, one blinded and one unblinded, and the average was used. The ratio of
time spent in the target chamber to the empty chamber was calculated for each phase and used
for data analysis.
The three-chamber sociability test also provided a method to determine the social
approach behaviors of the mice. Total frontal contact time was measured during phase 3. Frontal
contact time was determined to be any contact by the front half of the subject mouse with the
stranger mouse or cage. The behavior typically depicted itself when the stranger mouse had his
paws or face against the wire cage. Frontal contact was measured because the mouse could have
been in the target chamber but not have been socializing. One blinded scorer measured total
frontal contact time.
Self-Grooming test
Before testing began, the home cage was placed in the testing room with the filter paper
off for thirty minutes to habituate, in the same manner as the three-chamber test. Next, the mouse
was placed in a clean, empty, transparent mouse cage (7.5”x11.5”x5”) for ten minutes to
habituate (McFarlane et al., 2008). The mouse was then video recorded while in the singlechamber apparatus for the next ten minutes. The time spent spontaneously grooming during the
second ten-minute time period was recorded by two scorers, one of which was blinded. The
scores were then averaged. Grooming was determined according to the same criteria used in the
three-chamber sociability test. The single-chamber test occurred on a different day than the
three-chamber sociability test.
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Social Transmission of Food Preference
Social transmission of food preference is a task that has been used to measure
communication skills in rats and mice (Galef & Stein, 1985; Wrenn et al., 2003).
Mice were tested in groups of two to five. Twenty-four hours prior to testing, mice were
habituated to eating powdered food from jars. The cellulose, heptanoic, and octanoic pellets were
crushed so that dietary treatment would be maintained. The jars (2” diameter, 1.5” height) had
rounded bottoms and were made of glass. A small metal disk with holes was placed on top of the
food. A metal cover with a circular opening was placed on top of the disk to secure its
placement. The overall top to the jars was used to prevent the mice from burrowing into and
dispersing the food. After habituation, one cagemate (the demonstrator mouse) was placed in a
separate cage and given water for 18 hours. During this time period, all mice fasted. At 18 hours,
the demonstrator mouse was given one jar of powdered, flavored food (trained flavor). The
flavored food was made using regular pellet chow. After two hours, the amount of food the
demonstrator mouse had eaten was measured. If it had eaten at least 0.5 grams of the flavored
food, the mouse was placed back into its home cage. If it had not, it remained in isolation for
hour-long intervals until it had eaten at least 0.5 grams, at which point the mouse was reunited
with its cagemates. After thirty minutes of interaction in the home cage, the observer mice were
placed into separate cages and given the option of two flavored foods, the trained flavor and a
novel or untrained flavor. Again, the flavored food was made with regular pellet chow. After two
hours, the mice were placed back into their home cage. Jars were weighed before and after the
presentation of food to determine the amount that was eaten. Flavor pairs were 2% cocoa against
1% cinnamon and 1% cinnamon against 0.25% cumin (Ruskin et al., 2013).
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STFP is believed to measure the ability of the observers to detect olfactory cues from the
demonstrator mouse (Wrenn et al., 2003). Healthy mice engage in social transmission during the
thirty minutes and choose to eat the trained flavor because they have recognized the smell from
the demonstrator mouse. Mice showing autistic symptoms do not engage in the communication
behavior necessary for STFP to successfully take place, thus showing no preference for either the
trained or untrained flavor.
Rotarod testing
Rotarod testing assesses balance and motor coordination (Crawley, 2008; Moy et al.,
2004). The mouse is placed on a cylinder, which rotates and requires the mice to walk steadily
forward. If they do not, they will fall off of the cylinder. On the first day, mice were trained to
use the rotarod. They were placed on the rotarod for five minutes at a constant 5 revolutions per
minute (rpm). Thirty minutes later, the training session was repeated. On the day of testing, mice
were placed on the rotarod for five minutes at 5 rpm, gradually increasing to 40 rpm. Four trials
were conducted, with thirty-minute breaks in between each trial. The latency to fall from the
rotarod was recorded after each trial. The times recorded were collapsed across the four trials,
and these values were used for data analysis.
Statistical Testing
Outliers were removed if they were more than two standard deviations away from the
mean. If an outlier was present in the weight, ketone, glucose, or food intake levels at five or
eight weeks, that test subject was removed from all analyses, including behavioral testing. Less
than 5% and 6% of the subjects’ data were eliminated from weight and glucose data analysis and
individual behavioral test analysis, respectively. When the pellet and cellulose groups did not
differ, the heptanoic and octanoic treatment groups were only compared to the cellulose control.
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Otherwise, they were compared to the pellet control. One-way or two-way repeated measures
ANOVA was used for analysis, as appropriate. Post-hoc tests used were Tukey, for all pairwise
comparisons, and Bonferroni, for all comparisons to the pellet control or cellulose group.
ANOVA on ranks was used for the rotarod test. All data are presented as the mean (± SEM).

RESULTS
Weight and Blood
Body weight, glucose levels, and βHB levels of each mouse were measured at five weeks
and eight weeks. We found an unexpected difference with regard to baseline weights, with the
pellet control group having a significantly lower base weight, indicating that there was a poor
initial balancing of weights. However, weight increased significantly over the three weeks of
treatment in the pellet, cellulose, and octanoic groups. The heptanoic group did not show a
significant change in weight over time, but the weights were initially high; the heptanoic group
did not differ from the other groups after three weeks of treatment (Figure 3).
Glucose levels were not significantly affected by any particular treatment, and decreased
glucose levels were seen among all groups at eight weeks of age (Figure 4). With respect to
ketones, the cellulose treatment group showed a significant decrease in βHB levels after three
weeks of treatment whereas the octanoic group showed a significant increase as compared to all
others. Additionally, the octanoic group had significantly higher βHB levels at eight weeks
compared to the pellet control group, indicating that the octanoic group experienced a high level
of ketosis (Figure 5).
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Figure 3: Average body weights of mice in each treatment group at five weeks and eight
weeks of age. At baseline, weight was significantly lower in the pellet control group. Weight
significantly increased over the three weeks of treatment in the pellet, cellulose, and octanoic
groups. Factors for ANOVA: treatment p = 0.018; time p < 0.001; treatment x time p <0.001.
*** p ≤ 0.001, Tukey post-hoc compared to five weeks. # p ≤ 0.05, ### p ≤ 0.001, Tukey posthoc compared to pellet control (pellet: n=5; cellulose: n=8; heptanoic: n =10; octanoic: n=8).
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Figure 4: Average glucose levels of mice in each treatment group at five weeks and eight
weeks. Treatment did not have an effect on glucose levels. Factors for ANOVA: treatment p =
0.189; time p = 0.006; treatment x time p = 0.248 (pellet: n=5-8; cellulose: n=8; heptanoic: n=10;
octanoic: n=3-8).
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Figure 5: Average βHB levels of mice in each treatment group at five weeks and eight
weeks. The cellulose treatment group showed a significant decrease in βHB levels from five to
eight weeks of age whereas the octanoic group showed a significant increase. Compared to the
pellet control treatment group, the octanoic group had significantly higher βHB levels at eight
weeks. Factors for ANOVA: treatment p < 0.001; time p = 0.712; treatment x time p = 0.004. * p
≤ 0.05, ** p ≤ 0.01, Tukey post-hoc compared to five weeks. ### p ≤ 0.001, Tukey post-hoc
compared to pellet control (pellet: n=5-8; cellulose: n=8; heptanoic: n=10; octanoic: n=3-8).
Food Intake
The daily weight of food eaten was measured once a week over the course of treatment,
and the data was averaged in order to obtain an estimate of the daily food intake for each mouse.
However, because of varying caloric content, interpretation of the raw data must be done
cautiously. As such, caloric intake was calculated using the value of metabolizable energy of the
standard pellet chow (LabDiet2013) and the net energy value of MCTs (Ingle et al., 1999).
Although net energy accounts for heat loss while metabolizable energy does not, the heat loss in
mice is fairly small, so the values are highly comparable (L. Tracey, personal communication,
March 12, 2014). The mice in the cellulose treatment group had a higher caloric intake per gram
of body weight at eight weeks of age compared to the pellet control (Figure 6).
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Figure 6: Average daily caloric intake
per g of body weight at eight weeks of
age. Compared to the pellet control, the
cellulose treatment group had a higher
caloric intake of food during the last
week of treatment. Factor for ANOVA:
treatment p ≤ 0.001. *** p ≤ 0.001,
Bonferroni t-test compared to pellet
control (pellet: n=5; cellulose: n=8;
heptanoic: n=10; octanoic: n=8).
	
  
	
  

	
  
Three-Chamber Sociability
In the three-chamber test for sociability, the time the mouse spent during each of the three
phases was measured to check for side bias, preference for social interaction, and preference for
social novelty during phases 1, 2, and 3, respectively. The graph illustrates the data as the ratio of
time spent in the target chamber compared to the empty chamber (phase 2) or chamber with the
old stranger mouse (phase 3). Dietary treatments did not significantly influence sociability. None
of the mice showed a side preference during phase 1, and all groups spent more time with the
stranger mouse than the empty chamber during phase 2 (p = 0.008, Figure 7). This was
unexpected with the pellet and cellulose control groups.
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Figure 7: Relative sociability of mice as measured by the amount of time spent in a
chamber with a stranger mouse compared to an empty chamber (phase 2) and time spent
in a chamber with a novel mouse compared to the old stranger mouse (phase 3). The threechamber sociability test illustrated that treatment had no effect on sociability. Factors for
ANOVA: treatment p = 0.587; time p = 0.007; treatment x time p = 0.19 (pellet: n=8; cellulose:
n=8; heptanoic: n=9; octanoic: n=8).
Social Approach
In the three-chamber test, the total amount of time the mouse spent partaking in frontal
contact with either the novel or old stranger mouse during phase 3 was used to determine if the
mouse engaged in social approach. Compared to the cellulose control, the heptanoic and octanoic
treatment groups spent significantly more time engaging in social approach behaviors (Figure 8).
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Figure 8: Total amount of time
spent engaging in frontal contact
during phase 3 of the threechamber sociability test. Compared
to the cellulose group, the heptanoic
and octanoic treatment groups spent
significantly more time engaging in
frontal contact during phase 3. Factor
for ANOVA: treatment p ≤ 0.001.
*p ≤ 0.05, *** p ≤ 0.001 Bonferroni
t-test compared to cellulose control
(pellet:
n=7;
cellulose:
n=8;
heptanoic: n=9; octanoic: n=8).

Self-Directed Repetitive Behavior
The amount of time spent grooming during the single-chamber test and phases 1 and 2 of
the three-chamber test were used as an indicator of self-directed repetitive behavior. Compared
to the cellulose group in the single-chamber grooming task, the heptanoic and octanoic treatment
had no effect on self-directed repetitive behavior (Figure 9). During the three-chamber task, the
cellulose, heptanoic, and octanoic treatment groups spent significantly more time grooming in
phase 2, when the stranger mouse was present, than in phase 1. There were no significant
differences in the time spent grooming in the pellet treatment group or between experimental
groups during the three-chamber test (Figure 10).
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Figure 9: Amount of time spent
grooming during the singlechamber
grooming
task.
Treatment had no effect on selfdirected
repetitive
behaviors
compared to the cellulose group.
Factor for ANOVA: treatment p =
0.048. Bonferroni t-test compared
to cellulose (pellet: n=8; cellulose:
n=8; heptanoic: n=10; octanoic:
n=8).
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Figure 10: Amount of time spent grooming during phase 1 compared to phase 2 as a
measure of repetitive behaviors. The cellulose, heptanoic, and octanoic treatment groups spent
significantly more time grooming in phase 2 (presence of one stranger mouse) than in phase 1.
Factors for ANOVA: treatment p = 0.106; time p < 0.001; treatment x time p = 0.053. * p ≤ 0.05;
** p ≤ 0.01, Tukey post-hoc compared to phase 1 (pellet: n=8; cellulose: n=8; heptanoic: n=9;
octanoic: n=8).
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Social Transmission of Food Preference (STFP)
STFP was used as a relative measure of communication via olfactory cues. STFP was not
included for the pellet treatment due to technical errors. No significant differences were found
within or between experimental groups in the STFP test (Figure 11).
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Figure 11: Relative ability to communicate as demonstrated by the STFP test. No significant
differences were found in the STFP test. Mice in the pellet control group were not tested. Factor
for ANOVA: treatment p = 0.927; flavor p = 0.689; treatment x flavor p = 0.499 (cellulose: n=6;
heptanoic: n=7; octanoic: n=6).
Rotarod
The rotarod was used to test motor control and coordination. No significant differences
were found among or between experimental groups in the rotarod test (Figure 12). For statistical
purposes, the four trials were collapsed over time per mouse, and those values were used.
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Figure 12: Motor control as demonstrated by the rotarod test. Treatment had no effect on the
amount of time the mice spent on the rotarod. Factor for ANOVA on ranks: treatment p = 0.065
(pellet: n=7; cellulose: n=2; heptanoic: n=3; octanoic: n=3).

DISCUSSION
The major goal of this study was to determine the efficacy of MCTs and the role of
anaplerosis in establishing ketosis and alleviating autistic symptoms in mice. In order to carry
this out, BTBR mice were randomly assigned to a pellet, cellulose, heptanoic, or octanoic
treatment group. Body weight, glucose levels and βHB, and food intake were measured over the
course of treatment. Behavioral testing was conducted in order to quantify sociability and social
approach, repetitive behavior, communication, and motor coordination skills. The results from
the laboratory behavioral tests produced conflicting data regarding the efficacy of MCTs on
alleviating autistic symptoms. However, the MCT KDs increased ketones and trended towards
alleviating autistic symptoms, suggesting its mechanistic basis may be similar to that of the LCT
KD. Furthermore, a MCT KD is clinically relevant, and as such, should be investigated further.
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Rationale
Previous work has illustrated that a strict LCT KD (6.6:1 fats to proteins and
carbohydrates) alleviates autistic symptoms in the BTBR mouse model (Ruskin et al., 2013)
whereas a moderate and clinically relevant LCT KD was ineffective (Reuman, 2013). This work
suggests that the increase in ketone bodies due to the KD has an effect on the CNS that
consequentially results in the beneficial alleviation of autistic symptoms. Because MCTs are
hydrolyzed faster and more efficiently than LCTs (Labarthe et al., 2008), a lower ratio of fats to
proteins and carbohydrates is allotted, allowing a MCT KD to be clinically relevant, while
inducing the same effect as a LCT KD (Liu & Wang, 2013). Thus, it was hypothesized that a
MCT KD would induce a level of ketosis similar to that of the strict LCT KD because MCTs
have been shown to cause an increase in ketone bodies, ATP, and acetyl CoA (de Baulny &
Superti-Furga, 2006). It was further hypothesized that odd-numbered MCTs would be more
effective at alleviating autistic symptoms because they undergo anaplerosis, whereas evennumbered MCTs do not (Borges & Sonnewald, 2012). This suggests that an increase in ATP
and the subsequent increase in adenosine may also be a possible mechanism by which the KD
acts.
Pellet and Cellulose Control Groups
Initially, the intended control group for this study was a standard chow control diet
balanced with 17% cellulose. However, preliminary data analysis indicated that the cellulose
group did not display autistic symptoms, which is expected of the BTBR mouse strain
(McFarlane et al., 2008; Silverman, Yang, & Crawley, 2010). As a result, a group of mice solely
on the standard chow diet was added as another control. If there was no difference between the
pellet and cellulose groups, the cellulose group was used as the control in data analysis. The data
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regarding both the pellet control and cellulose groups for this study has been mostly inconsistent
with other studies, namely in the three-chamber test for sociability and repetitive behavior. As
such, all data must be regarded carefully. Future experiments might benefit from baseline
behavioral tests conducted before the administration of the diet to confirm autistic behaviors
before treatment.
Weight and Blood
Body weight and blood glucose and ketone levels were measured before treatment began
and at eight weeks of age. Body weight was measured in order to ensure that the diet did not
affect mouse growth and development or alter weight gain. In order to determine if the mice
were in ketosis, blood glucose and ketone levels were measured. Typically, the ketogenic diet
results in increased levels of ketones and decreased levels of glucose (Masino et al., 2013).
Unfortunately, the initial weights between the four treatment groups were not balanced
well; compared to the pellet control, the cellulose, heptanoic, and octanoic groups had
significantly greater weights at five weeks of age before treatment began. Nonetheless, the pellet,
cellulose, and octanoic groups showed a significant increase in weight at eight weeks of age
compared to five weeks. Only the mice in the heptanoic treatment group did not increase in
weight, although the weight at eight weeks was not different. If weight were expressed as the
percent of baseline, the heptanoic treatment group would not show any growth. However, the
average weights of all three treatment groups at eight weeks were similar. Furthermore, all mice
were in the weight range for their age group (Reuman, 2013). Because of the baseline weight
discrepancy, it is difficult to make any interpretations regarding weight and growth.
Glucose levels within any of the four treatment groups did not significantly change over
the course of treatment. In light of the risk of hypoglycemia associated with the LCT KD, the
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lack of significant difference of glucose levels is a promising aspect of the MCT KDs, indicating
that fewer medical risks may be associated with them.
Blood βHB levels suggest that the octanoic treatment group experienced a high level of
ketosis. βHB levels significantly increased in the octanoic treatment group and significantly
decreased in the cellulose group from five weeks of age to eight weeks. Because octanoic acid
promotes ketosis and bypasses glycolysis, the result was expected. However, no difference was
observed in the heptanoic treatment group although the same logic applies. The lack of a
measured effect of ketosis in the heptanoic group is most likely due to the fact that the Precision
Xtra Ketone Meter and Strips undergo a timed reaction between βHB dehydrogenase (received
from the blood sample) and NAD (in the strips) to produce NADH. The influx of electrons
causes an electrical change that then produces a detectable signal the meter can report. However,
because heptanoate is an odd-numbered MCT, the reaction that occurs uses β-hydroxy pentanoic
acid (which is produced from C5 ketone bodies) instead of βHB. The reaction with βHP is
approximately twenty times slower than that of the βHB reaction (Bergmeyer et al., 1967). As
such, the reaction would not be near completion by the time the meter reports the ketone levels,
which is probably why no change was observed regarding ketone levels in the heptanoic
treatment group. However, it can be reasonably assumed that the mice in the heptanoic treatment
group were in ketosis as heptanoate molecules can be broken down into C5 ketone bodies
(Borges & Sonnewald, 2012). Future studies should consider the inaccuracy in using the
Precision Xtra Meter to measure C5 ketones and utilize a different method.
Food Intake
The caloric intake of each treatment group is important in order to determine the
palatability of the diets and the relative impact the amount of food eaten may have had on
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altering the metabolism of the mice. When considering the caloric intake of the groups, only the
cellulose group had a significantly higher caloric intake than the pellet group, suggesting that the
heptanoic and octanoic treatment would not have affected growth. Furthermore, high levels of
fiber within the cellulose diet may have impeded digestion or made it more metabolically costly,
resulting in a higher caloric intake by the mice within that treatment group.
It is important to note two limitations. First of all, the pellets were placed in a wire cage
above the mice. Some food may have fallen out or have been lost in the bedding, impacting the
results obtained. Furthermore, the mice were housed socially, and the amount of food eaten over
the course of a day was calculated and divided by the number of mice in that particular cage.
Although we obtained an estimate, there is no specific data regarding the exact amount of food
each animal consumed.
Sociability and Social Approach
The three-chamber test is used to quantify sociability and social approach. Impairments
in social behaviors are characteristic of autism. In other studies, BTBR mice have shown
decreased levels of sociability, as measured by the time spent in a chamber with a stranger
mouse compared to an empty chamber (phase 2: preference for social interactions) and by the
time spent in a chamber with a novel mouse compared to the first stranger mouse (phase 3:
preference for social novelty) (McFarlane et al., 2008; Ruskin et al., 2013; Silverman et al.,
2010). However, the results from the sociability test were unusual. No significant effect of
treatment on sociability was illustrated. Rather, the time the pellet control spent in the target
chamber during phase 2 was unusually high with a ratio of approximately 0.7. In a study that
used BTBR mice and the same chow diet, the ratio of time spent in the target chamber during
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phase 2 was approximately 0.55 (Ruskin et al., 2013). Because the pellet control did not behave
as expected, no interpretation is available for the effect of treatment on sociability.
The three-chamber test also provided a measured social approach, which did not conform
to the results of sociability. No difference existed between the pellet and cellulose groups, so the
cellulose group was used as the control. Compared to the cellulose control, the heptanoic and
octanoic treatment groups spent significantly more time engaged in frontal contact, which is
what we expected. The amount of time the pellet and cellulose controls spent engaged in pellet
control was approximately the same as reported by Ruskin et al. (2013), illustrating that the
consistency and reliability of this test has been maintained and may be more indicative of social
behavior than the sociability measurement of the three-chamber test. Both the heptanoic and
octanoic treatment groups were in ketosis (or expected to be: see above) and showed a
significant increase in social approach behaviors, suggesting that a MCT KD has the potential to
alleviate autistic symptoms.
Self-Directed Repetitive Behavior
Self-grooming is a measure of self-directed repetitive behavior, which is characteristic of
individuals with autism. Repetitive behavior was measured in mice in a single-chamber selfgrooming test as well as during phase 1 and 2 of the three-chamber test. Because no difference
existed between the pellet and cellulose groups, the cellulose group was used as the control.
Compared to the cellulose control, treatment had no effect on self-directed repetitive behaviors.
These results are not easy to interpret clearly; for now they should be considered with care.
The grooming behavior during the three-chamber task is unclear. The cellulose,
heptanoic, and octanoic treatment groups all significantly groomed more in phase 2 compared to
phase 1. Furthermore, the time spent grooming in the pellet control group trended downward
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when it was expected to trend upwards in the presence of a stranger mouse. In Ruskin et al.,
(2013) BTBR mice on the pellet control diet spent significantly more time grooming in phase 2
compared to phase 1. Specifically, the mice spent approximately 50 s grooming during phase 1
and approximately 150 s grooming in phase 2. In this study, the mice spent approximately 110 s
grooming in phase 1 and 90 s grooming in phase 2. The inconsistency in results between studies
suggests that the results, again, should be considered carefully.
As it stands, the data suggests that the MCT KDs do not have an effect on alleviating
self-directed repetitive behavior. However, the lack of a reliable control makes the interpretation
difficult.
Communication
The social transmission of food preference task has been used to measure communication
skills in rats and mice (Galef & Stein, 1985; Wrenn et al., 2003). BTBR mice have shown
impairments in communication as illustrated by the STFP test, which is a behavioral
characteristic of people with autism (McFarlane et al., 2008). One shortcoming is that pellet
control group was not included due to technical errors. However, the cellulose group did not
exhibit STFP, suggesting that it may be a reliable control for this test. It was expected that the
heptanoic and octanoic treatment groups would eat significantly more of the trained flavor
compared to the untrained flavor; however this was not the case. Within each treatment group,
no significant difference was observed, most likely due to the high standard error and small
sample size.
Motor Control
Because those with ASD have been shown to have significant motor coordination defects
(Fournier et al., 2010), the rotarod test was used as a measure of motor control in the BTBR mice.
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Treatment had no effect on the time spent on the rotarod. Although there was a trend for a
positive effect in the heptanoic treatment group, the results are unclear because the sample size
of each group was relatively low, with one group having a sample size of two and two groups
having a sample size of three. More data needs to be collected before any interpretations can be
made, but the rotorod test does not seem to be impaired by the MCT KDs tested here.

SUMMARY & CONCLUSION
Overall, we found the MCT KD increased ketones, based on the octanoic group.
However, our behavioral findings were mixed. The mice in the pellet and cellulose groups did
not clearly exhibit autistic behaviors as expected, primarily in the three-chamber test for
sociability and repetitive behaviors. Furthermore, baseline weights were not balanced, βHB
levels were not measured accurately in the heptanoic treatment group, the pellet control group
was not included in analyses for deficits in communication, and the rotarod test had a very small
sample size. More work could resolve these issues. However, it is important to note that the
pellet and cellulose control mice did portray autistic behaviors in regards to the frontal contact
task, and the heptanoic and octanoic treatment groups spent significantly more time engaged in
frontal contact than the cellulose control, suggesting that the MCT KDs do have the potential to
alleviate autistic symptoms. Due to the aforementioned inconsistencies, it is difficult to draw
meaningful global interpretations, and all test-specific interpretations must be drawn cautiously.
The current study should be investigated further and expanded in order to understand the impact
of this metabolic treatment on autistic symptoms as well as the mechanism by which the KD
works.
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In conclusion, the results of the current study were conflicting and did not permit clear
interpretations. More data and a reliable control group are needed to establish a compelling case
for this treatment. Because a MCT KD metabolic treatment allows for a greater allowance of
proteins and carbohydrates, it is important to continue this investigation in hopes of becoming a
viable therapy for patients with autism.
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